Clinical trial
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Anti-Tumor Efficacy and Safety of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery (WU-KONG16)
NCT07182682 is registered in ClinicalTrials.gov with Dizal (Jiangsu) Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Anti-Tumor Efficacy and Safety of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery (WU-KONG16)
- Lead sponsor
- Dizal (Jiangsu) Pharmaceutical Co., Ltd.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- December 1, 2025
- Completion date
- January 31, 2031
- Enrollment
- 360 (estimated)
- Sites
- 49
Conditions
As the registry lists them; a condition with its own page is linked.
non-small cell lung cancer